$DXCM News

Did FDA-App Recalls and Activist Pressure Just Rewire Dexcom’s (DXCM) Software-Driven Investment Narrative?

Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience

Citigroup Maintains Buy on DexCom, Raises Price Target to $84

Signos raises $20M, expands Dexcom partnership for weight loss

Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users

DexCom Reveals Stolen Lots Of Scrapped Dexcom G7 Sensors Were Sold And Used By Customers, Launches Investigation With FDA And Authorities To Protect Patient Safety

DexCom Flex Launch Targets Wider Type 2 Market With Valuation Upside

Here's How Much You Would Have Made Owning DexCom Stock In The Last 15 Years

Harnessing medtech market alliances, ŌURA sets IPO plans in motion

Analysts Upgrade DexCom (DXCM) to “Outperform,” Driving Share Recovery

DexCom Might Finally Be Cheap Enough

The DexCom Stock Turnaround Is Showing Real Signs of Life

DXCM to Launch Dexcom Flex CGM System for Type 2 Diabetes in Germany

14. OURA

Canaccord Genuity Maintains Buy on DexCom, Lowers Price Target to $82

B of A Securities Maintains Buy on DexCom, Lowers Price Target to $80

Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany

Barclays Maintains Underweight on DexCom, Lowers Price Target to $64

DexCom Rolls Out Glucose Monitoring System Dexcom Flex In Germany

DexCom, Inc. (DXCM) Analyst/Investor Day - Slideshow